503A vs 503B compounding: what the FDA rules mean for GLP-1…

503A pharmacies are traditional compounding pharmacies that prepare medications for individual patients based on a valid prescription. They are regulated primarily by state pharmacy boards, with some federal oversight under Section 503A of the Federal Food, Drug, and Cosmetic Act. Examples include many independent specialty pharmacies.

503B outsourcing facilities are a different category, created by the Drug Quality and Security Act of 2013. They are FDA-registered facilities that can compound and sell large quantities of medications without requiring patient-specific prescriptions — essentially, commercial-scale compounding. They are subject to FDA's current Good Manufacturing Practice (cGMP) standards and more intensive federal oversight than 503A pharmacies.

During the semaglutide and tirzepatide shortage (roughly 2022–2025), both categories were legally permitted to compound these drugs. The shortage created an exemption that allowed compounded versions to reach patients when FDA-approved products were unavailable. When FDA removed semaglutide and tirzepatide from the drug shortage list, that exemption ended.

On April 1, 2026, the FDA issued a clarification reminding compounders of what conditions must be met for their preparations to remain legal following the shortage resolution.

Two key changes affect patients:

The "essentially a copy" rule for 503A pharmacies. The FDA clarified that semaglutide combined with additives such as vitamin B12 may now be considered an "essentially a copy" of an FDA-approved product — specifically, Wegovy or Ozempic. Compounding an essentially identical copy of an approved drug is generally not permitted under 503A rules unless a narrow exception applies. If your compounded GLP-1 included B12 or other additives, your pharmacy needs to evaluate whether that formulation remains permissible.

A monthly prescription cap. 503A compounding pharmacies are now limited to four or fewer prescriptions per calendar month for formulations that may fall under the essentially-a-copy category. This affects the scale at which small compounding pharmacies can serve multiple patients with these formulations.

For 503B outsourcing facilities, the picture is more categorical. These facilities are no longer on legal ground to compound semaglutide, tirzepatide, or liraglutide because:

1. The shortage-based legal exemption has ended
2. These drugs are not on the 503B Bulks List (which would otherwise permit compounding)
3. FDA proposed on April 30, 2026 (Federal Register notice 2026-08552) to formally and permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — meaning even future shortage conditions would not reopen the pathway if finalized

Public comment on the proposed exclusion closed June 29, 2026. If FDA finalizes the proposal, 503B compounding of these drugs would be permanently barred.

The commercial-scale compounded GLP-1 supply that reached many patients through telehealth platforms in 2023–2024 was sourced largely from 503B outsourcing facilities. That supply has ended.

503A pharmacies can continue to compound semaglutide and tirzepatide for individual patients under specific conditions:

• There must be a valid, patient-specific prescription
• The formulation must not be an essentially-a-copy of an FDA-approved drug, or must fall under a recognized exception
• The pharmacy must operate within the new monthly prescription limits

In practice, this means that a small number of 503A pharmacies may still legally prepare individualized compounded GLP-1 prescriptions for patients with documented medical necessity for a non-commercially-available formulation. This is not the same broad-access pathway that existed during the shortage.

Regardless of whether a compounded GLP-1 was produced by a 503A or 503B facility, it is not FDA-approved. This matters because FDA approval requires the manufacturer to demonstrate safety, efficacy, and quality manufacturing standards through a defined review process. Compounded preparations do not go through that process. Quality, sterility, concentration, and ingredient sourcing can vary.

The FDA has received over 455 adverse event reports linked to compounded semaglutide and over 320 linked to compounded tirzepatide. Many involved dosing errors from multi-dose vials. This does not mean all compounded GLP-1s caused these events — it means the adverse event signal is real and worth understanding.

If you are still receiving a compounded GLP-1 prescription, the most important questions to ask are:

1. Is this pharmacy a 503A pharmacy or a 503B outsourcing facility?
2. Does the formulation comply with the April 2026 FDA clarification, particularly regarding additives like B12?
3. Is the pharmacy operating within the monthly prescription limits?

These questions cannot be answered from the outside. Ask your prescribing clinician and your pharmacy directly. If your pharmacy cannot clarify its legal basis for compounding, that is itself a signal worth noting.

FDA's proposed permanent 503B exclusion is a proposal, not yet finalized. However, the direction is clear. A small number of 503A pharmacies may continue providing individualized compounded GLP-1 prescriptions under the current constraints, but the broad population-level compounding access that existed in 2023–2024 has substantially narrowed.

• Is my pharmacy a 503A pharmacy or a 503B outsourcing facility?
• Does my current formulation comply with the April 2026 FDA clarification, particularly if it includes additives?
• What is my pharmacy's legal basis for continuing to compound semaglutide or tirzepatide?
• What are my branded alternatives if my compounded formulation is no longer available?
• What is the clinical risk difference between my compounded prescription and an FDA-approved branded GLP-1?

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (April 1, 2026). fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
• Federal Register notice 2026-08552: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (April 30, 2026). federalregister.gov
• Pharmacy Times, Luke Halpern: FDA Moves to Permanently Close the Door on Compounded GLP-1s. pharmacytimes.com